Omnicell, Inc.(OMCL)Earnings, Financials & Key RatiosOmnicell, Inc. (OMCL) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
while the balance sheet is significantly healthier with a debt-to-equity ratio of 0.15, the company's razor-thin 5.4% operating margin in 2026Q1 and high reliance on stock-based compensation suggest limited near-term earnings visibility.
Omnicell, Inc. (OMCL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Omnicell, Inc. (OMCL) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 28, 2026 | $0.55vs $0.33+66.7% | $310Mvs $304M+1.9% |
| Q1 2026 | Feb 5, 2026 | $0.40vs $0.47-14.9% | $314Mvs $313M+0.2% |
| Q4 2025 | Oct 30, 2025 | $0.51vs $0.36+41.7% | $311Mvs $313M-0.9% |
| Q3 2025 | Jul 31, 2025 | $0.45vs $0.31+45.2% | $291Mvs $292M-0.5% |
Recent stock market news and headlines for Omnicell, Inc. (OMCL)
FORT WORTH, Texas--(BUSINESS WIRE)--Nnamdi Njoku appointed President of Omnicell leading global operations & innovation strategy; Randall Lipps continues as CEO, Chairman of the Board.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Investors interested in Medical Info Systems stocks are likely familiar with Omnicell (OMCL) and Hims & Hers Health, Inc. (HIMS). But which of these two companies is the best option for those looking for undervalued stocks?
Investors need to pay close attention to OMCL stock based on the movements in the options market lately.
Key metrics vs top competitors for Omnicell, Inc. (OMCL)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $45.24 | $2.06B | 1021.22 | 6.53% | 0.17% | 0.17% | — | |
| $155.54 | $56.35B | 26.68 | 8.23% | 5.33% | 4.54% | — | |
| $86.62 | $9.87B | 26.49 | 4.03% | 2.95% | 8.14% | — | |
| $784.23 | $94.27B | 20.43 | 12.36% | 1.18% | — | — | |
| $237.52 | $55.89B | 36.82 | -1.87% | 0.62% | — | — | |
| $192.01 | $31.19B | 35.30 | 16.34% | 28.37% | 13.36% | — |
Omnicell, Inc. (OMCL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Omnicell, Inc. (OMCL) SEC filings — annual & quarterly reports (10-K, 10-Q)
Apr 28, 2026·SEC
Feb 5, 2026·SEC
Dec 8, 2025·SEC
Get notified when OMCL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Omnicell, Inc. (OMCL) stock FAQ — growth, dividends, profitability & financials explained
Omnicell, Inc. (OMCL) reported $1.23B in revenue for fiscal year 2025. This represents a 1719% increase from $67.4M in 2000.
Omnicell, Inc. (OMCL) grew revenue by 6.5% over the past year. This is steady growth.
Yes, Omnicell, Inc. (OMCL) is profitable, generating $20.4M in net income for fiscal year 2025 (0.2% net margin).
Omnicell, Inc. (OMCL) has a return on equity (ROE) of 0.2%. This is below average, suggesting room for improvement.
Omnicell, Inc. (OMCL) generated $111.8M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
